Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07827586) titled 'Non-interventional Study of Subcutaneous Ocrelizumab in Persons With Relapsing-Remitting Multiple Sclerosis' on Sept. 15.
Study Type: Observational
Primary Sponsor: Hoffmann-La Roche
Condition:
Relapsing-Remitting Multiple Sclerosis
Intervention:
Drug: Ocrelizumab
Recruitment Status: Not recruiting
Date of First Enrollment: September 30, 2026
Target Sample Size: 1800
To know more, visit https://clinicaltrials.gov/study/NCT07827586
Published by HT Digital Content Services with permission from Health Daily Digest....